Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J3SW
|
|||
| Former ID |
DNC000286
|
|||
| Drug Name |
BCEAB
|
|||
| Synonyms |
CHEBI:6426; Ac-Leu-Leu-Arg-H; Ac-Leu-Leu-Argininal; Acetyl-L-leucyl-L-leucylargininal; N-Acetyl-L-leucyl-L-leucyl-L-argininal; 55123-66-5; UNII-J97339NR3V; J97339NR3V; 103476-89-7; Acetyl-Leu-Leu-Arg-al; Leupeptin hemisulfate; L-Leucinamide, N-acetyl-L-leucyl-N-(4-((aminoiminomethyl)amino)-1-formylbutyl)-; N-acetyl-L-leucyl-N-[(1S)-4-{[amino(imino)methyl]amino}-1-formylbutyl]-L-leucinamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C35H34N2O6
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1CC2C(N(C2=O)C(=O)NC(C3=CC=C(C=C3)C)C4=CC=C(C=C4)C)OC5=CC=C(C=C5)C(=O)O
|
|||
| InChI |
1S/C35H34N2O6/c1-4-42-30-8-6-5-7-27(30)21-29-32(38)37(33(29)43-28-19-17-26(18-20-28)34(39)40)35(41)36-31(24-13-9-22(2)10-14-24)25-15-11-23(3)12-16-25/h5-20,29,31,33H,4,21H2,1-3H3,(H,36,41)(H,39,40)/t29-,33+/m1/s1
|
|||
| InChIKey |
IGIOAZWNIRIBNB-CPBHLAHYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
602112, 7979525, 11121773, 11122253, 11362949, 11365511, 11368073, 11371069, 11371070, 11373674, 11376235, 16003641, 26756847, 43128595, 47944494, 48170149, 48413940, 49857450, 50061803, 50078012, 50111452, 53788333, 56231459, 57318714, 77099929, 92310124, 99301036, 99302556, 104060153, 104352924, 117585558, 127936552, 134339750, 134339752, 134339755, 134339756, 134340176, 135030613, 139421944, 160661376, 175267735, 184589588, 223653355, 226888611, 241182192, 241375264, 242084562, 249617260, 250132850, 252344670
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Chymase (CYM) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Renin-angiotensin system | |||
| Reactome | Activation of Matrix Metalloproteinases | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Development of a chymase inhibitor: pharmacological characterization of a chymase inhibitor in inflamed tissue remodeling and fibrosis. Jpn J Pharmacol. 2002 Nov;90(3):206-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.